{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:39:12Z","timestamp":1791189552102,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.amjcard.2010.01.363","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T05:16:06Z","timestamp":1268802966000},"page":"1802-1808","source":"Crossref","is-referenced-by-count":51,"title":["Observed and Predicted Reduction of Ischemic Cardiovascular Events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial"],"prefix":"10.1016","volume":"105","author":[{"given":"Ingar","family":"Holme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Boman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Brudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Egstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Gohlke-Baerwolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Antero","family":"Kes\u00e4niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Malbecq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B.","family":"Rosseb\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Wachtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Willenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2010.01.363_bib1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjcard.2006.10.064","article-title":"Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study","volume":"99","author":"Rosseb\u00f8","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.363_bib2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid-lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2010.01.363_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2010.01.363_bib4","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2010.01.363_bib5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1515\/CCLM.2004.254","article-title":"The apoB\/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk","volume":"42","author":"Walldius","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.amjcard.2010.01.363_bib6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"suppl A","key":"10.1016\/j.amjcard.2010.01.363_bib7","first-page":"A415","article-title":"Impact of severity of aortic valve stenosis on effect of intensive lipid lowering therapy","volume":"53","author":"Gerdts","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2010.01.363_bib8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2010.01.363_bib9","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2010.01.363_bib10","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2010.01.363_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease: insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Ann Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914910005229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914910005229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T09:59:25Z","timestamp":1544608765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914910005229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0002914910005229"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2010.01.363","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}